Monographie - Daunorubicin hydrochloride

Последно актуализиране :
19/11/2024

Daunorubicin hydrochloride

Химична структура

Търговско наименование

Търговските имена са примерни и съставът на помощните вещества може да бъде различен в зависимост от държавата и лабораториите

Cerubidin	Великобритания, Дания, Ирландия, Норвегия, Швеция
Cerubidine	Белгия, Канада, Люксенбург, Мароко, Съединени Американски щати / САЩ, Тунис, Турция, Франция, Холандия, Чили, Швейцария
D Blastin	Мароко
Daunac	Колумбия
Daunobin	Индия
Daunoblastin	Австрия, Германия
Daunoblastina	Венецуела, Гърция, Иран, Испания, Италия, Саудитска Арабия, Унгария
Daunocin	Индия, Малайзия, Перу
Daunogobbi	Аржентина
Daunomed	Индия, Перу
Daunomycin	Индия
Daunoplus	Индия
Daunorubicin	Австралия, Великобритания, Канада, нова Зеландия, Съединени Американски щати / САЩ
Daunorubicina	Еквадор, Колумбия, Мексико, Перу, Чили
Daunorubitec	Индия
Daunoside	Индия
Daunotec	Венецуела, Индия
Daurocina	Чили
Epodoxo	Перу
Maxidauno	Аржентина, Еквадор
Oncodaunotec	Колумбия
Rubilem	Мексико
Runabicon	Колумбия, Мексико
Zuleb	Мексико

Библиография : Daunorubicin hydrochloride

	Вид	Публикация
3	Списание	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Списание	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Списание	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Списание	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
148	Списание	Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm Weekbl [Sci] 1992 ; 14: 365-369.
150	Списание	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
152	Списание	Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J. Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion. Pharm Acta Helv 1995 ; 70: 141-148.
169	Списание	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
244	Списание	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Списание	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Списание	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Списание	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
492	Списание	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
632	Списание	Beijnen JH, Rosing H, De Vries PA, Underberg WJM. Stability of anthracycline antitumour agents in infusion fluids. J Parenter Sci Technol 1985 ; 39: 220-222.
643	Списание	Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR. In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. Cancer Treat Rep 1987 ; 71: 1189-1192.
686	Списание	Wood MJ, Irwin WJ, Scott DK. Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 1990 ; 15: 279-289.
905	Списание	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1265	Списание	Wood MJ, Irwin WJ, Scott DK. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography. J Clin Pharm Ther 1990 ; 15: 291-300.
1284	Списание	Williams BA, Tritton TR. Photoinactivation of anthracyclines. Photochem Photobiol 1981 ; 34: 131-134.
1410	Списание	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Списание	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1520	Лаборатория	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	Списание	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1897	Списание	Sautou-Miranda V, Brigas F, Thibault M, Chopineau J. Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage. EJHP 2001 ; 7, 3: 108-115.
1982	Списание	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	Списание	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3438	Списание	Respaud R, Quenum L, Plichon C, Tournamille J.F, Gyan E, Antier D, Viaud-Massuard M.C. A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids. J Pharm Biomed Anal 2013 ; 83 : 164-170.
3474	Лаборатория	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3540	Лаборатория	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3604	Лаборатория	Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012
3668	Лаборатория	Dexamethasone - Summary of Product Characteristics Hospira 2015

Mentions Légales